Replies to post #138278 on Biotech Values

[DewDiligence]

wouldn't the bigger deal be if idix has IP relating to 7977?

Not if the IP is worth a pittance in terms of royalties. Say for the sake of discussion that IDIX can get 1% of 7977’s US sales until the patent in question expires; the stock would still be way overvalued, IMHO.

[turtlepower]

IDIX/GILD - According to the 10K the composition of matter for 7977 is protected by the 572 patent.

Mericitabine (or RG7128). We own an issued U.S. patent (U.S. patent number 7,429,572) and pending U.S. and foreign patent applications directed to the PSI-6130 chemical compound, pharmaceutical formulations, therapeutic combinations and use to treat HCV infections. This patent was issued on September 30, 2008 and will expire on April 3, 2025. Any additional patents issuing from the pending applications would expire no earlier than 2024. We own an issued U.S. patent (U.S. patent number 7,601,820) and pending U.S. and foreign patent applications directed to the synthesis of PSI-6130 chemical compound, including synthetic intermediates thereof. This patent was issued on October 13, 2009 and will expire on November 13, 2025. Any additional patents issuing from the pending applications would expire no earlier than 2025. We and Roche co-own an issued U.S. patent (U.S. patent number 7,754,699) and pending U.S. and foreign patent applications directed to prodrugs of PSI-6130 (including mericitabine), therapeutic combinations and use to treat HCV infections. This patent was issued on July 13, 2010 and will expire on October 29, 2028. Any additional patents issuing from the pending applications would expire no earlier than 2028.
PSI-7977. The active drug composition of matter is protected by U.S. patent number 7,429,572 expiring April 3, 2025. In addition, we own pending U.S. and foreign patent applications directed to the PSI-7977 chemical compound, pharmaceutical formulations, use to treat HCV infections, and synthesis. Any patents issuing from the pending applications would expire no earlier than 2028. We own pending U.S. and foreign patent applications directed to processes for preparing the PSI-7977 chemical compound, including synthetic intermediates thereof. Any patents issuing from the pending applications would expire no earlier than 2030.

http://www.gurufocus.com/StockLink.php?type=sec&symbol=VRUS&date=2011-11-14&report=10-K